CONMED Corporation

CONMED Corporation

CNMDยทNYSE

$35.03

+3.5%
HealthcareMedical - Devices

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

At a Glance

Live Snapshot
Market Cap$1.05B
EPS1.5200
P/E Ratio23.05
Earnings Date07/29/2026
3Y+31.0%
5Y+59.0%
10Y+80.0%
3Y-158.0%
5Y+394.0%
10Y+221.0%
3Y+412.0%
5Y+165.0%
10Y+347.0%
CONMED Corporation

CONMED Corporation Profit Bridge

CNMD ยท NYSE
Revenue1.37B
Cost of Goods Sold (649.12M)
Gross Profit725.38M
Operating Expenses (584.24M)
Operating Income141.13M
Interest Expense (31.09M)
Other Income/Expense-70.01M
Pretax Income71.12M
Income Tax (24.06M)
Net Income47.05M
Net Income
47.05M

Profitability Analysis

Gross Margin

52.8%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

10.3%

Acceptable margins but limited operational leverage. Operating expense control is important.

Net Profit Margin

3.4%

Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.

Effective Tax Rate

33.8%

Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.

Profitability Insight

High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.

CONMED Corporation Income Statement

CNMD โ€ข NYSE

CONMED Corporation Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
1.4B
1.3B
1.2B
1B
1B
862.5M
955.1M
859.6M
796.4M
763.5M
719.2M
734.5M
756.8M
767.1M
725.1M
713.7M
694.7M
742.2M
694.3M
646.8M
GROSS PROFIT
(649.1M)
(574M)
(568.5M)
(474.2M)
(442.6M)
(402.2M)
(430.4M)
(390.5M)
(365.4M)
(355.2M)
(337.5M)
(336M)
(350.3M)
(361.3M)
(350.1M)
(348.3M)
(357.4M)
(359.8M)
(345.2M)
(334M)
725.4M
733M
676.2M
571.2M
568M
460.3M
524.7M
469.1M
431M
408.3M
381.7M
398.5M
406.5M
405.8M
374.9M
365.4M
337.3M
382.4M
349.1M
312.8M
OPERATING INCOME
(584.2M)
(532.7M)
(555.6M)
(501.2M)
(458.3M)
(414.3M)
(445.6M)
(397.8M)
(384.1M)
(370.7M)
(330.5M)
(345.7M)
(350M)
(340.6M)
(306.4M)
(308.3M)
(309.1M)
(307.1M)
(266.3M)
(317.4M)
(528.4M)
(478.3M)
(503M)
(454M)
(414.8M)
(373.8M)
(400.1M)
(355.6M)
(351.8M)
(338.4M)
(303.1M)
(293.9M)
(310.7M)
(302.5M)
(277.7M)
(276.5M)
(266.3M)
(272.4M)
(240.5M)
(234.8M)
(55.9M)
(54.4M)
(52.6M)
(47.2M)
(43.6M)
(40.5M)
(45.5M)
(42.2M)
(32.3M)
(32.3M)
(27.4M)
(27.8M)
(25.8M)
(28.2M)
(28.7M)
(29.7M)
(31.8M)
(33.1M)
(30.4M)
(30.7M)
141.1M
200.3M
120.6M
70.1M
109.7M
46M
79.1M
71.3M
46.9M
37.7M
51.2M
52.8M
56.5M
65.2M
8.3M
57.1M
28.3M
75.3M
81M
-4.6M
PRE-TAX INCOME
(31.1M)
(37.3M)
(39.8M)
(28.9M)
(35.5M)
(44.1M)
(42.7M)
(20.7M)
(18.2M)
(15.4M)
(6M)
(6.1M)
(5.6M)
(5.7M)
(6.7M)
(7.1M)
(7.1M)
(10.4M)
(16.2M)
(19.1M)
-31.1M
-37.3M
-39.8M
-28.9M
-35.5M
-44.1M
-42.7M
-20.7M
-18.2M
-15.4M
-6M
-6.1M
-5.6M
-5.7M
-10.6M
-11.4M
-7.1M
-10.4M
0.0
0.0
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-2.9M
(0.0)
(7.3M)
(8.8M)
(7.2M)
(0.0)
(2.2M)
(10.9M)
(1.6M)
-4.6M
(51.9M)
-70M
-37.3M
-39.8M
-140.9M
-36.6M
-44.4M
-47.9M
-20.7M
-18.2M
-18.3M
-6M
-6.1M
-5.9M
-5.7M
-59.4M
-11.4M
-10.1M
-6M
-13.4M
-19.8M
71.1M
163M
80.8M
-70.9M
73.1M
1.6M
31.2M
50.7M
28.7M
19.4M
45.1M
46.7M
50.6M
59.5M
-2.3M
45.7M
18.2M
69.3M
64.8M
-24.4M
NET INCOME
(24.1M)
(30.6M)
(16.4M)
(9.7M)
(10.6M)
-7.9M
(2.6M)
(9.8M)
-26.8M
(4.7M)
(14.6M)
(14.5M)
(14.7M)
(19M)
-3.1M
(15.3M)
(6M)
(24.7M)
(23.3M)
-11.9M
47.1M
132.4M
64.5M
-80.6M
62.5M
9.5M
28.6M
40.9M
55.5M
14.7M
30.5M
32.2M
35.9M
40.5M
752K
30.3M
12.1M
44.6M
41.5M
-12.5M

SEC Filings

CNMD - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

June 01, 2026
May 27, 2026
2026
8-K

8-K 2026

N/A

May 20, 2026
May 18, 2026
2026
10-Q

10-Q 2026 Q1

Q1

April 30, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 29, 2026
April 29, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 07, 2026
May 18, 2026
2026
8-K

8-K 2026

N/A

March 13, 2026
March 13, 2026
2026
10-K

10-K 2025 FY

FY

February 17, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

January 28, 2026
January 28, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
8-K

8-K 2026

N/A

January 08, 2026
January 06, 2026
2026
Showing 1 to 10 of 434 filings